港股上午盘三大指数集体收跌，止步4拉升行情！恒生指数跌0.29%险守26000点关口，国企指数、恒生 科技指数分别下跌0.48%及0.09%。市场做多情绪在连续4日上涨且创阶段新高后开始趋于谨慎。 另一方面，半导体芯片股拉升明显，英诺赛科涨超10%领衔，中芯国际涨6%，铜、铝等有色金属股表 现活跃，中资券商股、重型机械股、军工股、教育股、煤炭股、苹果概念股纷纷上涨。(格隆汇) 盘面上，连续上涨的大型科技股多数表现低迷，其中，美团跌近4%，百度跌2.38%，京东跌1.8%，小米 跌超1%，腾讯飘绿，阿里巴巴、网易小幅上涨；美媒指特朗普考虑对来自中国的药品实施严格限制， 生物医药股大幅下挫，创新药方向跌幅最大，其中，歌礼制药跌近13%，翰森制药跌超9%，石药集 团、百济神州、中国生物制药跟跌；影视娱乐股、新消费概念股、体育用品股、汽车股、航空股普遍走 低。 ...

Market Overview - The Hang Seng Index fell by 0.29%, down 75 points, closing at 26,124 points, while the Hang Seng Tech Index decreased by 0.09%. The early trading volume in Hong Kong stocks reached HKD 176.3 billion [1]. Pharmaceutical Sector - The pharmaceutical sector experienced a significant decline, with multiple stocks opening down over 10%. Reports indicate that the Trump administration is considering restrictions on Chinese pharmaceuticals. Notable declines include Hansoh Pharmaceutical down 9%, CSPC Pharmaceutical down 7.5%, and Innovent Biologics down 3.3% [1]. Metals Sector - The non-ferrous metals sector saw gains, driven by a quarter-on-quarter increase in basic metal performance. Companies such as China Hongqiao rose by 3.97%, Jiangxi Copper by 3.2%, and China Aluminum by 3.64% [1]. Semiconductor Industry - The semiconductor industry is expected to continue its "AI-driven + self-controlled" dual development trend in the second half of the year. Semiconductor stocks collectively rose, with Hua Hong Semiconductor and SMIC both increasing by over 5% [1]. Telecommunications - ZTE Corporation saw a rise of 7.62%, as the company accelerates its expansion from connectivity to computing power, with institutions optimistic about its stable performance [1]. Virtual Asset Trading - Yunfeng Financial surged over 18%, following a nearly 28% increase the previous day, after receiving approval to provide virtual asset trading services [2]. Fiber Optics - Longi Fiber Optics experienced a rise of over 14%, driven by increased demand for AI-driven data center interconnectivity, with institutions viewing the company as a core beneficiary [2]. Biotechnology - Rongchang Biopharmaceuticals increased by over 5%, as its drug Taitasip became the first biopharmaceutical to apply for listing in the field of Sjögren's syndrome globally [3]. Clinical Trials - Yaojie Ankang-B saw an increase of over 11%, with its market capitalization surpassing HKD 40 billion after receiving approval to conduct Phase II clinical trials for its drug Tienogitini [4]. Technology Sector - Huiju Technology rose over 10% after entering the Hong Kong Stock Connect list, with expectations of rapid growth in its MPO business over the coming years [5]. Strategic Partnerships - Charoen Pokphand International rose by 3% following a strategic partnership with Muyuan Group, as the company is a producer of the antibiotic goldmine under Charoen's umbrella [5]. Market Trends - Shenzhou Holdings increased by over 8%, driven by hot concepts and performance growth propelling its stock price [5].

Core Viewpoint - Goldman Sachs reports that the Trump administration is discussing restrictions on Chinese pharmaceuticals and drafting an executive order aimed at limiting the entry of innovative Chinese drugs into the U.S. market, which could create "headline risk" for the Chinese biotech/pharmaceutical sector and increase stock price volatility [1] Group 1: Short-term Stock Price Risk Analysis - Companies are categorized into three groups based on their global presence and partnerships: - The first group includes companies with established global operations (e.g., BeiGene, Legend Biotech), which are expected to be less affected due to their solid foundations in markets like the U.S. and low expectations for new transactions [2] - The second group consists of companies with strong global partners (e.g., Kelun Biotech, 3SBio, Hansoh Pharmaceutical, Hengrui Medicine), where the impact is minimal as the executive order primarily targets new licensing transactions, leaving already licensed assets largely unaffected [2] - The third group includes companies with high expectations for external licensing that have not yet materialized, further divided into those planning global clinical trials (e.g., Innovent Biologics, Zai Lab, CSPC) who may enhance clinical value through differentiated data, and those unable or unwilling to conduct global trials (e.g., Galactico, Eucure Biopharma, CStone Pharmaceuticals) who may need to expedite transactions before policy implementation [2] Group 2: Long-term Valuation Considerations - The long-term valuation of companies remains dependent on three core factors: - The quality of data and differentiated clinical value of their pipelines [2] - The execution capability of the companies [2] - The financial condition of the companies [2]

Group 1 - The core viewpoint of the article highlights the volatility in the Hong Kong innovative drug sector, with significant declines in stocks such as Hansoh Pharmaceutical, BeiGene, and CSPC Pharmaceutical, alongside a notable drop in the Hang Seng Medical ETF [1] - A report from The New York Times indicates that the Trump administration is considering stricter restrictions on innovative drugs from China, particularly experimental drugs, which may have limited substantive impact on domestic innovative drug companies [1] - Data from Huatai Securities shows that since 2025, there have been 540 global innovative drug business development transactions with a total disclosed amount of $163.41 billion, of which Chinese innovative drugs accounted for 83 license-out transactions totaling $84.53 billion, indicating the irreversible rise of Chinese innovative drugs [1] Group 2 - The article notes that foreign companies have faced a patent cliff since 2020, necessitating the acquisition of pipelines to fill a market gap exceeding $240 billion over the next decade, leading to increased lobbying efforts [2] - Long-term trends suggest that the aging population in China will drive steady growth in health consumption demand, forming a core logic for investment in the pharmaceutical sector [2] Group 3 - The Hang Seng Medical ETF (159892) is highlighted as a representative of the global pharmaceutical industry, with a decline of 3.3%, and its top ten weighted stocks include several innovative drug companies [3] - The Hong Kong Stock Connect Medical ETF (520510) focuses on CXO and AI healthcare, with a decrease of 1.88%, featuring leading companies such as WuXi Biologics and MicroPort Medical [3]

【导读】光模块、 PCB 概念股拉升走高，四会富仕走出 20cm 涨停，工业富联盘中涨停 中国基金报记者 晨曦 大家好！来一起关注最新的市场行情和资讯～ 9 月 11 日， A 股三大指数开盘涨跌不一。开盘后市场短线跳水，随后拉升回暖。截至发 稿， A 股主要指数集体飘红，深证成指涨超 1% ，创业板指涨 1.7% 。 | 3819.69 | 12683.34 | 2953.41 | | --- | --- | --- | | 上证指数 +0.20% | 深证成指 +1.00% | 创业板指 +1.69% | 盘面上，上午医药生物板块大幅下跌，传媒、纺织服饰、美容护理、社服等板块不振；农业 股盘初走高，光模块、电路板等概念股集体拉升。 | | | Wind热门概念指数 | | | --- | --- | --- | --- | | 覆铜板 4.49% | 电路板 4.50% | 光模块(CPO) 5.82% | 鸡产业 3.07% | | 射频及天线 3.27% | 生物育种 2.02% | 光芯片 3.81% | 服务器 2.95% | | 猪产业 | 玻璃纤维 | 抗生素 | 生物科技等权 | | --- ...

Group 1 - The core point of the news is that the Hong Kong innovative pharmaceutical sector experienced a significant decline, with major stocks dropping over 10% due to reports of potential restrictions on Chinese drugs by the Trump administration [1][2][5] - Key stocks affected include Basilea Pharmaceutica-B, Hansoh Pharmaceutical, and Kelun-B, all of which opened lower by 15%, 14.98%, and 12.97% respectively [1][2] - The decline in the innovative pharmaceutical sector also impacted related ETFs, with several Hong Kong Stock Connect innovative drug ETFs dropping over 6% in early trading [2] Group 2 - The report from The New York Times indicated that the Trump administration is drafting an executive order to impose strict limitations on Chinese pharmaceuticals, particularly experimental drugs, which contributed to the market's reaction [2] - In the U.S. market, companies like BeiGene and Zai Lab saw their stocks drop over 9% following the news [2] - Other sectors, such as technology stocks, also faced declines, with notable drops in companies like Baidu and Alibaba, while gold stocks showed some activity with gains [3] Group 3 - Looking ahead, the outlook suggests that as the A-share market enters a valuation digestion phase, expectations of U.S. Federal Reserve easing may provide marginal support for Hong Kong stock valuations [4] - The Hong Kong internet sector is highlighted for its potential due to self-developed AI chips and cloud business expansion, which could enhance earnings certainty [4] - Overall, the low valuation of Hong Kong stocks, combined with improved asset quality and increased corporate dividends and buybacks, may attract foreign capital inflows [4]

9月11日早盘，港股创新药集体暴跌，恒生生物科技指数一度跌超7%，中国生物制药、翰森制药、石药 集团、诺诚健华、百济神州、药明生物、药明康德（603259）等领跌；恒生医药ETF（159892）、港股 通医疗ETF（520510）跟随指数调整。 ③全球化趋势未发生根本转变，中国创新药凭借其研发效率和成本优势，依然是全球药企重要的合作伙 伴，2025年有望继续达成多项十亿级别以上的对外授权交易。 相关ETF： 港股通医疗ETF（520510）：聚焦CXO+AI医疗等主线，CXO含量全市场领先。 恒生医药ETF（159892）：聚焦创新药，同指数下规模最大，流动性良好。 从海外消息来看，一项草拟的行政命令威胁要切断从中国引进创新药的通道，一是美国制药公司从中国 药企收购药物权益的交易将面临更严格的审查，需接受美国外国投资委员会（CFIUS）的"强制性审 查"，二是要求FDA进行更严格审查并收取更高监管费用，阻止制药企业依赖来自中国患者的临床试验 数据。 以史为鉴，参考2024年生物安全法案对CXO的影响过程，创新药板块在短期内可能受情绪压制，市场 波动或难以避免；但从中长期看，行业向好的基本面并未改变： ①国内创 ...

Group 1 - The overall performance of the pharmaceutical industry is weak, with an average revenue growth of 1.6% and a decline in average net profit by 3.2% for the first half of 2025 compared to the full year of 2024 [2] - The industry is expected to take time for performance improvement, with ongoing support policies for innovative drugs and devices, as well as improvements in global biopharmaceutical financing driving recovery [2] - A significant drop in stock prices was observed among innovative drug concept stocks in the Hong Kong market, with Huaneng Pharmaceutical down nearly 15% and Kelun-Bio down over 12% [4] Group 2 - The report by CMB International analyzed the performance of 393 pharmaceutical companies listed in A-shares and Hong Kong stocks, indicating a deterioration in both revenue and profit compared to the previous year [2] - The domestic centralized procurement policy optimization and continuous support for innovative drugs and devices are seen as crucial for the industry's recovery [2] - The stock performance of various pharmaceutical companies reflects the overall market sentiment, with multiple companies experiencing declines exceeding 9% [4]

Market Overview - The A-share market opened with mixed results, with the Shanghai Composite Index down by 0.16%, the Shenzhen Component Index up by 0.11%, and the ChiNext Index up by 0.46% [3][4] - The Hang Seng Index opened down by 0.81%, and the Hang Seng Tech Index fell by 0.97% [6][7] Pharmaceutical Sector Performance - The innovative drug concept stocks experienced significant declines, with BeiGene falling over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like Hengrui Medicine, Junshi Biosciences, and Kelun Pharmaceutical dropping over 5% [2][6] - The pharmaceutical sector as a whole saw a downturn, with various sub-sectors such as medical services, weight loss drugs, and CRO concepts all reporting negative performance, with declines ranging from -1.13% to -1.99% [5] Notable Stock Movements - Specific stocks such as Hansoh Pharmaceutical and WuXi Biologics dropped over 10%, while Jiangsu Hengrui Medicine and Junshi Biosciences also faced significant losses [6] - Conversely, some stocks like Jiujiuwang Pharmaceutical saw a rise of 5% despite the overall market trend [6]

Market Overview - The innovative drug concept stocks opened significantly lower, with BeiGene dropping over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like HengRui Medicine, Junshi Biosciences, and Kelun Pharmaceutical falling over 5% [3][4]. - The A-share market showed mixed results, with the Shanghai Composite Index down 0.16%, while the Shenzhen Component Index rose 0.11% and the ChiNext Index increased by 0.46% [4][5]. Sector Performance - The healthcare sector experienced a decline, with various sub-sectors such as medical services, CRO concepts, and innovative drugs all showing negative performance, with declines ranging from -1.99% to -1.44% [6]. - The Hong Kong market also opened lower, with the Hang Seng Index down 0.81% and the Hang Seng Tech Index falling 0.97%. Pharmaceutical stocks in Hong Kong saw significant drops, with companies like Hansoh Pharmaceutical and WuXi Biologics declining over 10% [6][7]. Notable Stocks - Specific stocks highlighted include BeiGene, WuXi AppTec, and Tigermed, which are part of the innovative drug sector and faced substantial declines in their stock prices [3][4]. - In the Hong Kong market, Hansoh Pharmaceutical and WuXi Biologics were noted for their significant drops, while a few stocks like Jiujiuwang Technology showed resilience with a 5% increase [6][7].